Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
45 hedge funds and large institutions have $18.4M invested in Agile Therapeutics in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 14 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 49 → 45 (-4)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
40% less capital invested
Capital invested by funds: $30.5M → $18.4M (-$12.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$3.79M |
| 2 |
D.E. Shaw & Co
New York
|
+$1.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$275K |
| 4 |
VF
Virtu Financial
New York
|
+$148K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$563K |
| 2 |
Morgan Stanley
New York
|
-$310K |
| 3 |
NIM
Needham Investment Management
New York
|
-$272K |
| 4 |
E
Ergoteles
New York
|
-$203K |
| 5 |
FMBTD
First Midwest Bank Trust Division
Joliet,
Illinois
|
-$124K |
AGRX Hedge Fund Activity: Q4 2021 in Review
45 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q4 2021, worth a combined $18.4M — down 40% from $30.5M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of AGRX and 10 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 12 added.
The largest buyer was Perceptive Advisors, adding an estimated $3.79M. The largest seller was Royal Bank of Canada, cutting an estimated $563K.
- 45 institutional investors held Agile Therapeutics (AGRX) as of Q4 2021, down from 49 in Q3 2021.
- Funds reported $18.4M of Agile Therapeutics stock for Q4 2021, down 40% quarter-over-quarter.
- 10 funds opened new Agile Therapeutics positions in Q4 2021 and 14 closed out, a net change of -4 holders.
- The largest Agile Therapeutics buyer in Q4 2021 was Perceptive Advisors, an estimated $3.79M added.
- The largest Agile Therapeutics seller in Q4 2021 was Royal Bank of Canada, an estimated $563K sold.
Based on aggregated 13F filings for Q4 2021.